144 related articles for article (PubMed ID: 23148419)
1. Conjugating phosphospermines to siRNAs for improved stability in serum, intracellular delivery and RNAi-mediated gene silencing.
Paris C; Moreau V; Deglane G; Karim L; Couturier B; Bonnet ME; Kedinger V; Messmer M; Bolcato-Bellemin AL; Behr JP; Erbacher P; Lenne-Samuel N
Mol Pharm; 2012 Dec; 9(12):3464-75. PubMed ID: 23148419
[TBL] [Abstract][Full Text] [Related]
2. Cationic siRNAs provide carrier-free gene silencing in animal cells.
Nothisen M; Kotera M; Voirin E; Remy JS; Behr JP
J Am Chem Soc; 2009 Dec; 131(49):17730-1. PubMed ID: 19928854
[TBL] [Abstract][Full Text] [Related]
3. Structure Tuning of Cationic Oligospermine-siRNA Conjugates for Carrier-Free Gene Silencing.
Nothisen M; Bagilet J; Behr JP; Remy JS; Kotera M
Mol Pharm; 2016 Aug; 13(8):2718-28. PubMed ID: 27398779
[TBL] [Abstract][Full Text] [Related]
4. Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor.
Lavigne C; Slater K; Gajanayaka N; Duguay C; Arnau Peyrotte E; Fortier G; Simard M; Kell AJ; Barnes ML; Thierry AR
Expert Opin Biol Ther; 2013 Jul; 13(7):973-85. PubMed ID: 23289797
[TBL] [Abstract][Full Text] [Related]
5. Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity.
Kubo T; Yanagihara K; Takei Y; Mihara K; Morita Y; Seyama T
Mol Pharm; 2011 Dec; 8(6):2193-203. PubMed ID: 21985606
[TBL] [Abstract][Full Text] [Related]
6. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
Bartlett DW; Davis ME
Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
[TBL] [Abstract][Full Text] [Related]
7. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing.
Harborth J; Elbashir SM; Vandenburgh K; Manninga H; Scaringe SA; Weber K; Tuschl T
Antisense Nucleic Acid Drug Dev; 2003 Apr; 13(2):83-105. PubMed ID: 12804036
[TBL] [Abstract][Full Text] [Related]
8. Bacterial delivery of siRNAs: a new approach to solid tumor therapy.
Xu DQ; Zhang L; Kopecko DJ; Gao L; Shao Y; Guo B; Zhao L
Methods Mol Biol; 2009; 487():161-87. PubMed ID: 19301647
[TBL] [Abstract][Full Text] [Related]
9. SiRNAs conjugated with aromatic compounds induce RISC-mediated antisense strand selection and strong gene-silencing activity.
Kubo T; Yanagihara K; Takei Y; Mihara K; Sato Y; Seyama T
Biochem Biophys Res Commun; 2012 Oct; 426(4):571-7. PubMed ID: 22982308
[TBL] [Abstract][Full Text] [Related]
10. Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell.
Qin J; Xu Y; Li X; Wu Y; Zhou J; Wang G; Chen L
Exp Mol Pathol; 2014 Feb; 96(1):1-8. PubMed ID: 24211718
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric siRNA targeting the bcl‑2 gene inhibits the proliferation of cancer cells in vitro and in vivo.
Yin Y; Chen X; Zhang CD; Liu PF; Duan YR; Fan YR; Wu ZW; Fu GF; Wang JJ; Xu GX
Int J Oncol; 2013 Jan; 42(1):253-60. PubMed ID: 23135004
[TBL] [Abstract][Full Text] [Related]
12. Efficacious gene silencing in serum and significant apoptotic activity induction by survivin downregulation mediated by new cationic gemini tocopheryl lipids.
Kumar K; Maiti B; Kondaiah P; Bhattacharya S
Mol Pharm; 2015 Feb; 12(2):351-61. PubMed ID: 25438085
[TBL] [Abstract][Full Text] [Related]
13. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
14. SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment.
Liu H; Li Y; Mozhi A; Zhang L; Liu Y; Xu X; Xing J; Liang X; Ma G; Yang J; Zhang X
Biomaterials; 2014 Aug; 35(24):6519-33. PubMed ID: 24797882
[TBL] [Abstract][Full Text] [Related]
15. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
16. Anionic amino acid-derived cationic lipid for siRNA delivery.
Suh MS; Shim G; Lee HY; Han SE; Yu YH; Choi Y; Kim K; Kwon IC; Weon KY; Kim YB; Oh YK
J Control Release; 2009 Dec; 140(3):268-76. PubMed ID: 19567256
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
[TBL] [Abstract][Full Text] [Related]
18. Gene-silencing potency of symmetric and asymmetric lipid-conjugated siRNAs and its correlation with dicer recognition.
Kubo T; Yanagihara K; Sato Y; Nishimura Y; Kondo S; Seyama T
Bioconjug Chem; 2013 Dec; 24(12):2045-57. PubMed ID: 24274056
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA nunchucks with a hydrophobic linker for efficient intracellular delivery.
Jo SD; Kim JS; Joe CO; Mok H; Nam YS
Macromol Biosci; 2014 Feb; 14(2):195-201. PubMed ID: 24106091
[TBL] [Abstract][Full Text] [Related]
20. Cell-penetrating cationic siRNA and lipophilic derivatives efficient at nanomolar concentrations in the presence of serum and albumin.
Perche P; Nothisen M; Bagilet J; Behr JP; Kotera M; Remy JS
J Control Release; 2013 Aug; 170(1):92-8. PubMed ID: 23639452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
